|
rs1517037
|
|
Pancreatic carcinoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10<sup>-14</sup>), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10<sup>-10</sup>), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10<sup>-8</sup>), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10<sup>-8</sup>). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA.
|
29422604 |
2018 |
|
rs9564966
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two genomewide association studies on pancreatic cancer have identified a novel single-nucleotide polymorphism of rs9564966 G > A on 13q22.1 region.
|
30537204 |
2019 |
|
rs889312
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP8 rs1045485 [odds ratio (OR), 0.78; 95% confidence interval (95% CI), 0.65-0.9; P = 0.005] and MAP3K1 rs889312 (OR, 0.85; 95% CI, 0.74-0.97; P = 0.017) showed evidence of association with risk of pancreatic cancer.
|
19843670 |
2009 |
|
rs7675998
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, we present a novel genome-wide candidate SNP for PDAC risk (TERT-rs2736100), a completely new signal (NAF1-rs7675998) approaching genome-wide significance and we report a strong association between the teloscore and risk of pancreatic cancer, suggesting that telomeres are a potential risk factor for pancreatic cancer.
|
30325019 |
2019 |
|
rs6001516
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
As a result, we identified two potential susceptibility loci (rs5757573 and rs6001516) of PDGFB associated with PC risk [odds ratio (OR) = 1.10, 95% confidence interval (CI) = 1.05-1.16, and p = 4.70 × 10<sup>-5</sup> for the rs5757573 C allele and 1.21, 1.11-1.32, and 2.01 × 10<sup>-5</sup> for the rs6001516 T allele].
|
29168174 |
2018 |
|
rs36115365
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Herein, we investigated the modifying capacities of rs36115365-C on PC and melanoma in a cohort of 283 p16-Leiden carriers including 29 diagnosed with PC, 171 diagnosed with melanoma, 21 diagnosed with both PC and melanoma and 62 with neither PC nor melanoma.
|
31203567 |
2019 |
|
rs2980879
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results showed that the rs2980879 polymorphism was associated with pancreatic cancer [allele: P = 0.023434, genotype: P = 0.03005; odds ratio (OR) and 95% confidence interval (CI) = 0.727788 (0.552664-0.958404)], whereas the rs2980874 polymorphism had no association with pancreatic cancer [allele: P = 0.749885, genotype: P = 0.699533; OR and 95%CI = 1.041981 (0.809196-1.341734)], and the rs2235108 polymorphism was not associated with the disease [allele: P = 0.629475, genotype: P = 0.547534, OR and 95%CI = 1.128290 (0.690829-1.842770)].
|
25117373 |
2014 |
|
rs1552462
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
When both stages were combined, we observed suggestive associations with PanCa for rs10887710 (MAT1A) (OR 1.13, 95 %CI 1.04-1.23), rs1552462 (SYT9) (OR 1.27, 95 %CI 1.02-1.59), and rs7074891 (CUBN) (OR 1.91, 95 %CI 1.12-3.26).
|
23334854 |
2013 |
|
rs12029406
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results showed that the rs3790843 (GA vs GG: OR=0.86, CI=0.76-0.98, <i>P</i>=0.992; GA+AA vs GG: OR=0.83, CI=0.73-0.94, <i>P</i>=0.950; A vs G: OR=0.85, CI=0.78-0.93, <i>P</i>=0.802), rs3790844 (CC vs TT: OR=0.65, CI=0.54-0.78, <i>P</i>=0.617; CC vs TT+CT: OR=0.73, CI=0.62-0.85, <i>P</i>=0.742; C vs T: OR=0.78, CI=0.73-0.84, <i>P</i>=0.555) and rs12029406 (TT vs CC: OR=0.73, CI=0.61-0.89, <i>P</i>=0.483; TT vs CC+CT: OR=0.78, CI=0.66-0.92, <i>P</i>=0.648; T vs C: OR=0.87, CI=0.79-0.95, <i>P</i>=0.837) polymorphisms were associated statistically with the risk of pancreatic cancer.
|
29785120 |
2018 |
|
rs10887710
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
When both stages were combined, we observed suggestive associations with PanCa for rs10887710 (MAT1A) (OR 1.13, 95 %CI 1.04-1.23), rs1552462 (SYT9) (OR 1.27, 95 %CI 1.02-1.59), and rs7074891 (CUBN) (OR 1.91, 95 %CI 1.12-3.26).
|
23334854 |
2013 |
|
rs199976573
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
These data suggest that resveratrol inhibits pancreatic cancer stem cell characteristics in human and Kras(G12D) transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.
|
21304978 |
2011 |
|
rs505922
|
|
Pancreatic carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
This study provided evidence of SNP rs505922 C allele as a strong risk factor of cancer susceptibility, specifically for pancreatic cancer.
|
25656610 |
2015 |
|
rs505922
|
|
Pancreatic carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Consistent with earlier reports showing a higher risk of PC for individuals with the non-O blood type, the previously reported protective allele (T) for rs505922 was found to be strongly correlated (r(2) = 0.96) with the O allele.
|
21306478 |
2011 |
|
rs505922
|
|
Pancreatic carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
SNP rs505922, located within the first intron of the ABO gene, has been associated with the adenocarcinoma subtype of pancreatic cancer.
|
22642827 |
2012 |
|
rs505922
|
|
Pancreatic carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 x 10(-8); multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28).
|
19648918 |
2009 |
|
rs1229984
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk.
|
19812523 |
2010 |
|
rs1229984
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The impact of alcohol and polymorphisms in aldehyde dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
|
19068087 |
2009 |
|
rs150495372
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The impact of alcohol and polymorphisms in aldehyde dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
|
19068087 |
2009 |
|
rs35385902
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk.
|
19812523 |
2010 |
|
rs35385902
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The impact of alcohol and polymorphisms in aldehyde dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
|
19068087 |
2009 |
|
rs698
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk.
|
19812523 |
2010 |
|
rs1693482
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The impact of alcohol and polymorphisms in aldehyde dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
|
19068087 |
2009 |
|
rs1501299
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We genotyped 7 single-nucleotide polymorphisms (SNPs) in PPARG2 (rs1801282), ADIPOQ (rs1501299), ADRB3 (rs4994), KCNQ1 (rs2237895), KCNJ11 (rs5219), TCF7L2 (rs7903146), and CDKAL1 (rs2206734), and examined their associations with pancreatic cancer risk in a multi-institute case-control study including 360 cases and 400 controls in Japan.
|
25516658 |
2014 |
|
rs4994
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We genotyped 7 single-nucleotide polymorphisms (SNPs) in PPARG2 (rs1801282), ADIPOQ (rs1501299), ADRB3 (rs4994), KCNQ1 (rs2237895), KCNJ11 (rs5219), TCF7L2 (rs7903146), and CDKAL1 (rs2206734), and examined their associations with pancreatic cancer risk in a multi-institute case-control study including 360 cases and 400 controls in Japan.
|
25516658 |
2014 |
|
rs1209809979
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The impact of alcohol and polymorphisms in aldehyde dehydrogenase 2 (ALDH2) Glu504Lys, alcohol dehydrogenase (ADH) 1B His48Arg, and ADH1C Arg272Gln on PC risk was examined with multivariate analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
|
19068087 |
2009 |